疼痛干预在急性心肌梗死中的综合效应

doi:10.3969/j.issn.1674-490X.2024.01.004

摘要/Abstract

摘要： 急性心肌梗死作为冠状动脉疾病最严重的情况常伴有剧烈的胸痛,疼痛不仅降低了患者的治疗依从性,而且通过增加心肌耗氧、加重心脏负荷、诱发冠状动脉血管痉挛加重病情。因此,及时干预剧烈胸痛在急性心肌梗死的治疗中至关重要。现就急性心肌梗死疼痛发生机制、阿片类药物以及非甾体抗炎药在急性心肌梗死中的应用进行综述。

关键词: 急性心肌梗死, 阿片, 非甾体抗炎药, 疼痛, 心肌保护, 抗血小板

Abstract: Acute myocardial infarction, as the most severe condition of coronary artery disease, is often accompanied by severe chest pain, which not only reduces the patient's treatment compliance, but also worsens the condition by increasing myocardial oxygen consumption, increasing cardiac load, and inducing coronary vasospasm. Therefore, timely intervention of severe chest pain is essential in the treatment of acute myocardial infarction. This article reviews the mechanism of pain in acute myocardial infarction, the use of opioids and non-steroidal anti-inflammatory drugs in acute myocardial infarction.

Key words: acute myocardial infarction, opioids, non-steroidal anti-inflammatory drugs, pain, myocardial protection, antiplatelet

中图分类号:

江永正,梁天乐,贾辛未. 疼痛干预在急性心肌梗死中的综合效应[J]. 医学研究与教育, 2024, 41(1): 27-33.

参考文献

[1] FU L W, LONGHURST J C. Regulation of cardiac afferent excitability in ischemia[J]. Handb Exp Pharmacol, 2009(194): 185-225. DOI: 10.1007/978-3-540-79090-7_6.
[2] ZAHNER M R, LI D P, CHEN S R, et al. Cardiac vanilloid receptor 1-expressing afferent nerves and their role in the cardiogenic sympathetic reflex in rats[J]. J Physiol, 2003, 551(Pt 2): 515-523. DOI: 10.1113/jphysiol.2003.048207.
[3] HEADRICK J P, PEPE S, PEART J N. Non-analgesic effects of opioids: cardiovascular effects of opioids and their receptor systems[J]. Curr Pharm Des, 2012, 18(37): 6090-6100. DOI: 10.2174/138161212803582360.
[4] ZATTA A J, KIN H, YOSHISHIGE D, et al. Evidence that cardioprotection by postconditioning involves preservation of myocardial opioid content and selective opioid receptor activation[J]. Am J Physiol Heart Circ Physiol, 2008, 294(3): H1444-1451. DOI: 10.1152/ajpheart.01279.2006.
[5] 杨欢,鲍静影,蒋苗苗,等. 阿片受体激动剂的镇痛作用及其靶点通路研究进展[J]. 安徽医药, 2017, 21(2): 211-215. DOI: 10.3969/j.issn.1009-6469.2017.02.005.
[6] 崔凤侠,刘丽艳,陈治宇. δ阿片受体结构及其镇痛机制[J]. 承德医学院学报, 2005(3): 252-254. DOI: 10.15921/j.cnki.cyxb.2005.03.040.
[7] 李桥波,舒海华,叶芳,等. 不同剂量喷他佐辛抑制吗啡的镇痛作用[J]. 中国疼痛医学杂志, 2016, 22(2): 102-108. DOI: 10.3969/j.issn.1006-9852.2016.02.005.
[8] PEART J N, PATEL H H, GROSS G J. Delta-opioid receptor activation mimics ischemic preconditioning in the canine heart[J]. J Cardiovasc Pharmacol, 2003, 42(1): 78-81. DOI: 10.1097/00005344-200307000-00012.
[9] FERDINANDY P, HAUSENLOY D J, HEUSCH G, et al. Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning[J]. Pharmacol Rev, 2014, 66(4): 1142-1174. DOI: 10.1124/pr.113.008300.
[10] 周谊,乔宏庆,马福成,等. 心肌梗死早期缺血再灌注与心交感神经损伤的实验研究[J]. 心脏杂志, 2004, 16(1): 29-32,36. DOI: 10.13191/j.chj.2004.01.32.zhouy.009.
[11] MASLOV L N, OELTGEN P R, LISHMANOV Y B, et al. Activation of peripheral delta opioid receptors increases cardiac tolerance to arrhythmogenic effect of ischemia/reperfusion[J]. Acad Emerg Med, 2014, 21(1): 31-39. DOI: 10.1111/acem.12286.
[12] LOCATI E T, BAGLIANI G, CECCHI F, et al. Arrhythmias due to inherited and acquired abnormalities of ventricular repolarization[J]. Card Electrophysiol Clin, 2019, 11(2): 345-362. DOI: 10.1016/j.ccep.2019.02.009.
[13] LASUKOVA T V, MASLOV L N, NIZKODUBOVA S W, et al. Role of intracellular calcium and cyclic nucleotides in realization of cardioprotective effects of δ1- and κ1-opioid receptor agonists[J]. Bull Exp Biol Med, 2009, 148(6): 877-880. DOI: 10.1007/s10517-010-0840-4.
[14] 修俭. κ阿片受体对心肌梗死后牵张诱导的电生理变化的影响[D]. 哈尔滨: 哈尔滨医科大学, 2012: 42.
[15] KHO C, LEE A, HAJJAR R J. Altered sarcoplasmic reticulum calcium cycling: targets for heart failure therapy[J]. Nat Rev Cardiol, 2012, 9(12): 717-733. DOI: 10.1038/nrcardio.2012.145.
[16] HAN F, HUI Z G, ZHANG S X, et al. Induction of haemeoxygenase-1 improves FFA-induced endothelial dysfunction in rat aorta[J]. Cell Physiol Biochem, 2015, 35(3): 1230-1240. DOI: 10.1159/000373946.
[17] RAJANI S F, IMANI A, FAGHIHI M, et al. Post-infarct morphine treatment mitigates left ventricular remodeling and dysfunction in a rat model of ischemia-reperfusion[J]. Eur J Pharmacol, 2019, 847: 61-71. DOI: 10.1016/j.ejphar.2019.01.023.
[18] SANTOS M, WEST E, SKALI H, et al. Resting heart rate and chronotropic response to exercise: prognostic implications in heart failure across the left ventricular ejection fraction spectrum[J]. J Card Fail, 2018, 24(11): 753-762. DOI: 10.1016/j.cardfail.2018.09.015.
[19] BOLTE C, NEWMAN G, SCHULTZ JEL J. Hypertensive state, independent of hypertrophy, exhibits an attenuated decrease in systolic function on cardiac kappa-opioid receptor stimulation[J]. Am J Physiol Heart Circ Physiol, 2009, 296(4): H967-H975. DOI: 10.1152/ajpheart.00909.2008.
[20] WESTMAN P C, LIPINSKI M J, LUGER D, et al. Inflammation as a driver of adverse left ventricular remodeling after acute myocardial infarction[J]. J Am Coll Cardiol, 2016, 67(17): 2050-2060. DOI: 10.1016/j.jacc.2016.01.073.
[21] IWASZKIEWICZ K S, SCHNEIDER J J, HUA S S. Targeting peripheral opioid receptors to promote analgesic and anti-inflammatory actions[J]. Front Pharmacol, 2013, 4: 132. DOI: 10.3389/fphar.2013.00132.
[22] 聂登云,吕志刚. 调节阿片受体MOR胞内信号转导的分子机制研究进展[J]. 中国疼痛医学杂志, 2019, 25(10): 725-731. DOI: 10.3969/j.issn.1006-9852.2019.10.002.
[23] CAMILLERI M, DROSSMAN D A, BECKER G, et al. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation[J]. Neurogastroenterol Motil, 2014, 26(10): 1386-1395. DOI: 10.1111/nmo.12417.
[24] GIL V, DOMINGUEZ-RODRIGUEZ A, MASIP J, et al. Morphine use in the treatment of acute cardiogenic pulmonary edema and its effects on patient outcome: a systematic review[J]. Curr Heart Fail Rep, 2019, 16(4): 81-88. DOI: 10.1007/s11897-019-00427-0.
[25] ARONOW W S. Heart-failure-complicating acute myocardial infarction[J]. Clin Geriatr Med, 2007, 23(1): 123-139. DOI: 10.1016/j.cger.2006.08.005.
[26] HOBL E L, STIMPFL T, EBNER J, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial[J]. J Am Coll Cardiol, 2014, 63(7): 630-635. DOI: 10.1016/j.jacc.2013.10.068.
[27] MEINE T J, ROE M T, CHEN A Y, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative[J]. Am Heart J, 2005, 149(6): 1043-1049. DOI: 10.1016/j.ahj.2005.02.010.
[28] THIEMERMANN C, ZACHAROWSKI K. Selective activation of E-type prostanoid(3)-receptors reduces myocardial infarct size. A novel insight into the cardioprotective effects of prostaglandins[J]. Pharmacol Ther, 2000, 87(1): 61-67. DOI: 10.1016/s0163-7258(00)00069-3.
[29] XIAO C Y, HARA A, YUHKI K, et al. Roles of prostaglandin I(2)and thromboxane A(2)in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors[J]. Circulation, 2001, 104(18): 2210-2215. DOI: 10.1161/hc4301.098058.
[30] MERRILL G, MCCONNELL P, VANDYKE K, et al. Coronary and myocardial effects of acetaminophen: protection during ischemia-reperfusion[J]. Am J Physiol Heart Circ Physiol, 2001, 280(6): H2631-H2638. DOI: 10.1152/ajpheart.2001.280.6.H2631.
[31] GOLFETTI R, VANDYKE K, RORK T, et al. Acetaminophen in the post-ischemia reperfused myocardium[J]. Exp Biol Med(Maywood), 2002, 227(11): 1031-1037. DOI: 10.1177/153537020222701112.
[32] MERRILL G F, GOLDBERG E. Antioxidant properties of acetaminophen and cardioprotection[J]. Basic Res Cardiol, 2001, 96(5): 423-430. DOI: 10.1007/s003950170023.
[33] MERRILL G F. Acetaminophen and low-flow myocardial ischemia: efficacy and antioxidant mechanisms[J]. Am J Physiol Heart Circ Physiol, 2002, 282(4): H1341-H1349. DOI: 10.1152/ajpheart.00716.2001.
[34] HADZIMICHALIS N M, BALIGA S S, GOLFETTI R, et al. Acetaminophen-mediated cardioprotection via inhibition of the mitochondrial permeability transition pore-induced apoptotic pathway[J]. Am J Physiol Heart Circ Physiol, 2007, 293(6): H3348-H3355. DOI: 10.1152/ajpheart.00947.2007.
[35] CHAN A T, MANSON J E, ALBERT C M, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events[J]. Circulation, 2006, 113(12): 1578-1587. DOI: 10.1161/CIRCULATIONAHA.105.595793.
[36] MITCHELL J A, WARNER T D. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs[J]. Nat Rev Drug Discov, 2006, 5(1): 75-86. DOI: 10.1038/nrd1929.
[37] CIPOLLONE F, PRONTERA C, PINI B, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability[J]. Circulation, 2001, 104(8): 921-927. DOI: 10.1161/hc3401.093152.
[38] SOWERS J R, WHITE W B, PITT B, et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus[J]. Arch Intern Med, 2005, 165(2): 161-168. DOI: 10.1001/archinte.165.2.161.
[39] MASCLEE G M C, STRAATMAN H, ARFE A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: a nested case-control study from the SOS project[J]. PLoS One, 2018, 13(11): e0204746. DOI: 10.1371/journal.pone.0204746.